Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Show more
Location: 822 A1A North, Ponte Vedra, FL, 32082, United States | Website: https://www.cadrenal.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
20.7M
52 Wk Range
$8.12 - $22.90
Previous Close
$9.97
Open
$10.00
Volume
15,741
Day Range
$9.99 - $10.20
Enterprise Value
16.33M
Cash
3.86M
Avg Qtr Burn
-2.956M
Insider Ownership
25.59%
Institutional Own.
9.38%
Qtr Updated
09/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Tecarfarin Details End-Stage Renal Disease , Systemic thromboembolism, Atrial fibrillation | Phase 3 Initiation | |
Tecarfarin Details Left Ventricular Assist Devices Patients | Phase 2 Update | |
Frunexian (Factor XIa Inhibitor) Details Thrombosis Associated With Cardiopulmonary Bypass And Cardiac Devices | Phase 2 Initiation |